They lost more than twice as much money in 2020 ($1.17B) as in 2019 ($580M). Despite a $12.6M tax benefit in 2020 vs. $12.4M tax provision in 2019.
But stonks.
You can see that their gross profit is up 2020 vs. 2019 ($740M vs. $500M).
You can follow along with the presentation they're showing at the top of their investor relations page.
https://t.co/LqyBBJAVhr
Karp is emphasizing Palantir's usage by "clandestine services" and "oil companies".
(CC @moiragweigel)
"It can make your military slightly more efficacious"
Difficult to quickly summarize, so read:
https://t.co/2d9KMFBWlN
He is on a long overview of the history of noone believing Palantir could succeed. Whether due to their maniacal data focus or their transfer from government to business ('which had no history').
(Hard to disagree on that one.)
It would be interesting to compare this to public procurement to estimate the amount of non-public government / non-US/UK contracts.
First Q: "Should investors expect choppy growth rates?"
Response is that Palantir is expanding through channel partnerships -- potentially to "(tens of?) thousands of customers" and drops the "sensor to shooter" income from DoD. "It's about the power of Apollo"
COO Shyam Sankar again answered this one. He mentions Demo Day Double-Click in April that should be announced soon.
A: Half of growth is driven by sales reps. But more in government. Not comfortable fully commenting on productivity yet.
A replay is supposedly available at the following numbers, but I called both and the person on the other end said you need the ID associated with the replay (which Palantir doesn't seem to provide).
https://t.co/nuEzDfgFGT
More from Finance
You May Also Like
Keep dwelling on this:
Further Examination of the Motif near PRRA Reveals Close Structural Similarity to the SEB Superantigen as well as Sequence Similarities to Neurotoxins and a Viral SAg.
The insertion PRRA together with 7 sequentially preceding residues & succeeding R685 (conserved in β-CoVs) form a motif, Y674QTQTNSPRRAR685, homologous to those of neurotoxins from Ophiophagus (cobra) and Bungarus genera, as well as neurotoxin-like regions from three RABV strains
(20) (Fig. 2D). We further noticed that the same segment bears close similarity to the HIV-1 glycoprotein gp120 SAg motif F164 to V174.
https://t.co/EwwJOSa8RK
In (B), the segment S680PPRAR685 including the PRRA insert and highly conserved cleavage site *R685* is shown in van der Waals representation (black labels) and nearby CDR residues of the TCRVβ domain are labeled in blue/white
https://t.co/BsY8BAIzDa
Sequence Identity %
https://t.co/BsY8BAIzDa
Y674 - QTQTNSPRRA - R685
Similar to neurotoxins from Ophiophagus (cobra) & Bungarus genera & neurotoxin-like regions from three RABV strains
T678 - NSPRRA- R685
Superantigenic core, consistently aligned against bacterial or viral SAgs
Further Examination of the Motif near PRRA Reveals Close Structural Similarity to the SEB Superantigen as well as Sequence Similarities to Neurotoxins and a Viral SAg.
The insertion PRRA together with 7 sequentially preceding residues & succeeding R685 (conserved in β-CoVs) form a motif, Y674QTQTNSPRRAR685, homologous to those of neurotoxins from Ophiophagus (cobra) and Bungarus genera, as well as neurotoxin-like regions from three RABV strains
(20) (Fig. 2D). We further noticed that the same segment bears close similarity to the HIV-1 glycoprotein gp120 SAg motif F164 to V174.
https://t.co/EwwJOSa8RK
In (B), the segment S680PPRAR685 including the PRRA insert and highly conserved cleavage site *R685* is shown in van der Waals representation (black labels) and nearby CDR residues of the TCRVβ domain are labeled in blue/white
https://t.co/BsY8BAIzDa
Sequence Identity %
https://t.co/BsY8BAIzDa
Y674 - QTQTNSPRRA - R685
Similar to neurotoxins from Ophiophagus (cobra) & Bungarus genera & neurotoxin-like regions from three RABV strains
T678 - NSPRRA- R685
Superantigenic core, consistently aligned against bacterial or viral SAgs